Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on EquityReturn on Sales

Summit Therapeutics (SMMT) EBT Margin (2016 - 2022)

Historic EBT Margin for Summit Therapeutics (SMMT) over the last 6 years, with Q3 2022 value amounting to 7700.0%.

  • Summit Therapeutics' EBT Margin changed N/A to 7700.0% in Q3 2022 from the same period last year, while for Dec 2024 it was 2943.23%, marking a year-over-year increase of 5.5651520379798105e22%. This contributed to the annual value of 11174.75% for FY2022, which is 62769100.0% down from last year.
  • According to the latest figures from Q3 2022, Summit Therapeutics' EBT Margin is 7700.0%.
  • Summit Therapeutics' EBT Margin's 5-year high stood at 1645.07% during Q1 2019, with a 5-year trough of 7700.0% in Q3 2022.
  • Moreover, its 4-year median value for EBT Margin was 1283.13% (2018), whereas its average is 2258.65%.
  • Per our database at Business Quant, Summit Therapeutics' EBT Margin surged by 1733600bps in 2018 and then tumbled by -50088000bps in 2019.
  • Summit Therapeutics' EBT Margin (Quarter) stood at 1392.35% in 2018, then crashed by -349bps to 6255.65% in 2019, then surged by 63bps to 2296.25% in 2020, then crashed by -235bps to 7700.0% in 2022.
  • Its EBT Margin stands at 7700.0% for Q3 2022, versus 2296.25% for Q1 2020 and 6255.65% for Q4 2019.